Doctor profile · Federal record
Dr. Manisha Mittal, MD
Rheumatology Physician (CMS: Rheumatology) · Fresno, CA
- NPI 1154627776
- Accepts Medicare
- MIPS 7.5 / 100 · 2023
- 21 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
2475 E Fir Ave Ste 104
Fresno, CA 937200398
(559) 900-4013
fax (559) 900-4172 - Mailing address
-
7045 N Maple Ave Ste 101
Fresno, CA 937208008
Credentials & registration
- NPI registered
- January 2011 — 15 yrs on file
- Profile last updated
- May 6, 2024
- Year of graduation
- 2005 — 21 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- California #A126113
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1154627776. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
158,935
Distinct HCPCS
10
Medicare allowed
$2,570,247
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 115,200 | 42 | $5 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 20,000 | 27 | $13 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13,400 | 23 | $42 | |
J3245 |
Injection, tildrakizumab, 1 mg | 6,900 | 20 | $138 | |
J0897 |
Injection, denosumab, 1 mg | 1,440 | 13 | $23 | |
96401 |
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 602 | 71 | $77 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 479 | 215 | $130 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 469 | 86 | $138 | |
J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg | 127 | 21 | $5 | |
96415 |
Administration of chemotherapy into vein, each additional hour | 123 | 21 | $30 |
In context: peer comparison
Among 5 peers in this city , average services per provider: 6,570. This provider delivers 24× the peer median.Open Payments
Industry payments received
All-time total
$1,164
Transactions
50
Manufacturers
9
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen Inc. | 15 | $384.16 | |
| GlaxoSmithKline, LLC. | 10 | $233.30 | |
| AstraZeneca Pharmaceuticals LP | 9 | $185.97 | |
| Janssen Biotech, Inc. | 6 | $137.83 | |
| Fresenius Kabi USA, LLC | 2 | $67.45 | |
| Ardelyx, Inc. | 3 | $53.14 | |
| UCB, Inc. | 2 | $41.68 | |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35.79 | |
| E.R. Squibb & Sons, L.L.C. | 1 | $25.12 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
429
Patients
126
Total drug cost
$609,185
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate | Generic | 127 | 51 | $6,338 |
| Prednisone | Generic | 91 | 38 | $680 |
| Enbrel Sureclick (Etanercept) | Brand | 62 | 0 | $465,233 |
| Methotrexate (Methotrexate Sodium) | Brand | 61 | 25 | $2,315 |
| Mycophenolate Mofetil | Generic | 29 | 12 | $2,250 |
| Allopurinol | Generic | 28 | 0 | $340 |
| Humira(Cf) Pen (Adalimumab) | Brand | 18 | 0 | $131,377 |
| Diclofenac Sodium | Generic | 13 | 0 | $653 |
Hospital affiliations
Frequently asked questions
What is Dr. Manisha Mittal's medical specialty?
Dr. Manisha Mittal practices Rheumatology Physician in Fresno, CA.
Where does Dr. Manisha Mittal practice?
Dr. Manisha Mittal practices at 2475 E Fir Ave Ste 104, Fresno, CA 937200398. Office phone: 5599004013.
What is Dr. Manisha Mittal's NPI?
Dr. Manisha Mittal's National Provider Identifier (NPI) is 1154627776, issued by NPPES.
Does Dr. Manisha Mittal accept Medicare assignment?
Yes. Dr. Manisha Mittal accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Manisha Mittal commonly perform?
Top Medicare-reported procedures in 2023: Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129). Source: CMS Medicare Physician & Other Practitioners file.